Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography

Intern Med. 2008;47(23):2053-6. doi: 10.2169/internalmedicine.47.1462. Epub 2008 Dec 1.

Abstract

We report a 56-year-old man who underwent monitoring of the response to chemotherapy of malignant pleural mesothelioma (MPM). (8)F-fluoro-2-deoxy-(D)-glucose positron emission tomography (FDG-PET) and computed tomography (CT) were performed prior to chemotherapy and after the first and second courses of chemotherapy. The tumor lesion exhibited shrinkage on CT and a decrease in the standardized uptake value (SUV) max after the first course of chemotherapy, but exhibited size enlargement and an increase in SUV max after the second course of chemotherapy. These findings suggest that results of quantification of metabolic response by FDG-PET are related to the objective response as determined by CT in patients with MPM.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Drug Monitoring / methods*
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Mesothelioma / diagnostic imaging
  • Mesothelioma / drug therapy*
  • Middle Aged
  • Pleural Neoplasms / diagnostic imaging
  • Pleural Neoplasms / drug therapy*
  • Positron-Emission Tomography / methods*

Substances

  • Antineoplastic Agents
  • Fluorodeoxyglucose F18